Re: The synergy of rosuvastatin (Crestor) with apabetalone
in response to
by
posted on
Oct 06, 2019 09:12AM
Bear is it so important to evaluate BOM on event rates when the top-line is based on time to the first occurrence. In other words, if the ABL wins on the least number of 3 point mace events and not statistically significant as compared to placebo when it comes to time to the first occurrence of each event, why do we pay so much attention comparing the number of placebo & apabetalone event rates?
Koo